Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
26 oct. 2023 11h09 HE
|
Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.
World-Leading Gene Editing Technology Unveiled in United Kingdom
23 oct. 2023 12h38 HE
|
Research and Markets
Dublin, Oct. 23, 2023 (GLOBE NEWSWIRE) -- In a momentous stride toward the future of agriculture, scientists have recently achieved a remarkable breakthrough in the realm of gene editing. The...
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
17 oct. 2023 06h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
US Gene Editing Market Poised for Unprecedented Growth: Rice University's Breakthrough Technology Shines
10 oct. 2023 10h08 HE
|
Research and Markets
Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- In the midst of remarkable discoveries in gene editing, researchers at Rice University have unveiled a groundbreaking improvement to traditional CRISPR...
Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase
05 oct. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society
28 sept. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
26 sept. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and...
Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
19 sept. 2023 09h00 HE
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
14 sept. 2023 12h00 HE
|
Epic Bio
- Vast high-throughput screening study used to train unique machine learning algorithm to design synthetic activators - - Rational engineering produced activators that induce the most...